•  
  •  
 

Problems and perspectives in pharmaceutics and drug discovery

Abstract

By experiments on studying of influence of preparation К-26 on synthesis DNA and RNA, an expres-sion of MDR2 drug resistance gene and p53 gene it is established, that in tumor cells the preparation sup-presses synthesis DNA and RNA than etoposide. Low level of an expression MDR2 gene (within 15 %) in comparison with for the most expression of this gene under influence etoposide is observed. The gene ex-pression р53 considerably increases to 80 % (at etoposide to 55 %), that defines big ability К-26 to induce tumor apoptosis. Higher level of an expression of gene MDR2 in spleen cages (55 %) under the influence of prepara-tion К-26 that reflects the big sensitivity of a tumor to a new preparation, than a susceptibility of normal body is simultaneously observed. Also in spleen cells the smaller expression of p53 gene caused К-26 in comparison with etoposide is observed, that specifies in less destructive influence К-26 on a spleen. There-upon, there are strong reasons to study preparation К-26 overcoming resistance for the subsequent influ-ence on a kidney cancer

First Page

101

Last Page

106

References

1. Yenikeyeva Z.M., Ibragimov A.A. Novuy Mass tsitostatikov so stimufyatsiyey koloniy eobrazuyuilix yedinits na selezenke (KOYEs). Tashkent, iz-vo "Fanvatexnologiya", 173s yuin B.. Genii. Moskva, "Mir", 1987, 544s. Maniatis T, Frich SembntkDj. Molekufyamove klonirovaniye. Metodu geneticheskoy injenerii. Moskva. "Mir". 1984. Rukovodstvo po ximioterapii opuxolevux zvbolevayemy. Pod red N.I.Perevodchikovoy. Izd ".Prakricheskaya meditsina, M.,2013g Samnsenko A. V. Mexanizmu gibeli kletokpri deystvii olivomitsina iyegoproizvodnux. Avtoref, k.m.n, Moskva-2009,19s. Stcnrovskaya A. A. Kletochmie mexanizmu mnojestvennoy lekarsrvennoy ustoychivosti opuxolevux kletok/А.А. Stavrovskaya Bioximiya. -2000. - T. 65. 4.-S. 112-126. Shtil A A. Razvitiye mnojestvennoy lekarstvennoy ustoychivosti как srochnuy otvet kletki na ekzogenmie vozdeystviya : Biol. МетЪгапй. -2003. -20(3). - S. 236-243. 8. BaguleyB.C. Multidrug Resistance in Cancer /B.C. Baguley //Methods in Molecular Biology. —2010. — Vol. 596. — P. 1-14. 9. Filipits M. Mechanisms of cancer: multidrug resistance / M. Filipits //Drug Discovery Today: Disease Mechanisms. — 2004. - Vol. 1. -№2. - P. 229-234. 10. Fracasso PM. Brady MF. Moore DH. Walker JL. Rose PG. Letvak L. Grogan TM, McGuire WP: Phase 11 study of paclitaxel and valspodar (.PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol 2001, 19:2975-2982. 11. Goldstein L.J. Expression of a multidrug resistance gene in human cancers / L.J. Goldstein H. Galski. A. Fojo el al. // J.Nat. Cancer Inst. 1989. — Vol. 81.-P. 116-124. 12. Hegewisch-Becker S. The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives / S. HegewiscfhBecker. D.K. Hossfeld//Ann. Hemalol.—1996.—Vol. 72. —P. 105-117. 13. Shah N.P. Mechanisms of resistance to ST1571 in Philadelphia chromosome-associated leukemias / N.P.Shah. C.LSawyers//Oncogene. -2003. - Vol. 22. -P. 7389-7395. 14. Shtil A.A. Emergence of multidrug resistance in leukemia cells during chemotherapy: mechanisms and prevention / А.Л. Shtil// J.Hematother. Stem Cell Res. -2002. - Vol. 11.-P. 231-241..

Share

COinS